秒速时时彩

CSPC Ranks No. 1 in the Top 10 Enterprises in Hebei Pharmaceutical Industry

Posted: December 9, 2019 Posted by: CSPC




On December 9, the third meeting of the Third Board of Directors of the Hebei Pharmaceutical Industry Association (Expansion) was held in Shijiazhuang. At the meeting, it was decided to award Shiyao Holding Group Co., Ltd. with the "Top 10 Pharmaceutical Industry in Hebei Province in 2018" and "Hebei Pharmaceutical in 2018" "Big profit and tax" title, awarded to Sinopharm Group Hebei Zhongcheng Pharmaceutical Co., Ltd. "2018 Hebei Pharmaceutical Distribution Industry Advantage Enterprise" title, awarded to Sinopharm Group Ouyi Pharmaceutical Co., Ltd. scientific research project "Technical Development and International Development of Azithromycin Raw Materials and Preparations" First Prize of "2017 Hebei Province Pharmaceutical Industry Science and Technology Progress".


aa_copy.jpg

22_Copy.jpg

33_Copy.jpg

44_ Copy.jpg


At the meeting, the Provincial Pharmaceutical Industry Association stated that under the situation of increasing downward pressure on the industry in the province, the pharmaceutical industry is outperforming, and the industrial added value and growth rate are among the top in the province's major industries. The pharmaceutical commerce and pharmaceutical logistics industries also Has achieved remarkable results.

The inspector is wise, and the homeopath wins. With the support of the Provincial Pharmaceutical Industry Association and all sectors of the society, CSPC has firmly implemented the strategy of innovation and internationalization, and has completed a gorgeous turn from general drug operation to innovative drug operation, achieving sustainable, healthy and rapid development of. Currently, there are more than 10 pharmaceutical production bases in Hebei, Jin, Shandong, Jiangsu, Jiangsu, Tianjin and other provinces and cities. The products are sold in more than 100 countries and regions around the world, with 34 varieties and single varieties sold over 100 million yuan. In 2018, the Group's sales revenue reached 30.068 billion yuan, and various taxes paid 2.76 billion yuan, which made outstanding contributions to the development of China's pharmaceutical industry and regional economic construction.